# NeogenTC

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/neogentc

- Industry: Pharmaceuticals
- Headquarters: Seoul, South Korea
- Website: http://www.neogentc.com
- Total disclosed funding: $13M
- Latest round: Series A (Apr 6, 2021)
- Investors on record: 9

## About

Based in Seoul, South Korea and founded in 2020, NeogenTC Corp. is a company specializing in immune cell therapy such as tumor-infiltrating lymphocyte cell therapy and T-cell receptor (TCR) modified T-cell (TCR-T) therapy with its own platform technology. The TCR-T cell therapy developed by Neogen TC is a T-cell receptor-transformed T-cell, which is a gene cell therapy product that incorporates various state-of-the-art technologies such as discovery of new antigens, T-cell receptor (TCR) sequence analysis, and gene transfer technology. The company's research and development on T-cell enginering began in 2017, followed by a Neoantigen-specific T-cell research which was selected by the Oncology Immunity Research Group from Asan Medical Center in 2018. In 2019, its research in Tumor-infiltrating lymphocyte (TIL) cell therapy development was selected by Ministry of Health and Welfare as a health care technology project. NeogenTC Corp. has recently completed its series A funding worth KRW 15 billion in investment from DSC Investment, Quad Ventures, TS Investment, Seoul Investment Partners, Login Best, Tigris Investment, Cosine Investment, and Cha Partners. 

NeogenTC Corp. is developing immune cell therapy such as tumor-infiltrating lymphocyte cell therapy and T-cell receptor (TCR) modified T-cell (TCR-T) therapy with its own platform technology based on tumor immunology. 

The company plans to expand and relocate its headquarters and research institute to Hanam-si, Gyeonggi-do in the second half of 2021, recruit human resources for R&D, expand infrastructure for research facilities and to build its own TCR-T platform technology as a TCR-T cell therapy that can target solid cancers that are difficult to treat.

## Funding rounds

- Series A, Apr 6, 2021, $13M — Seoul Investment Partners, DSC Investment, T.S. Investment, Cosine Investment, QUAD Ventures, Tigris Investment, Tcha Partners, Log Investment
- Seed, Jun 1, 2020 — Bluepoint Partners

## Investors

- Bluepoint Partners (https://capitalatlas.ai/funds/bluepoint-partners) — Seed
- Seoul Investment Partners (https://capitalatlas.ai/funds/seoul-investment-partners) — Series A
- DSC Investment (https://capitalatlas.ai/funds/dsc-investment) — Series A
- T.S. Investment (https://capitalatlas.ai/funds/t-s-investment) — Series A
- Cosine Investment — Series A
- QUAD Ventures (https://capitalatlas.ai/funds/quad-ventures) — Series A
- Tigris Investment (https://capitalatlas.ai/funds/tigris-investment) — Series A
- Tcha Partners — Series A
- Log Investment (https://capitalatlas.ai/funds/log-investment) — Series A